Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.56 |
| ▸ | CNR2 | P34972 | 11/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235650 | 0.88 | CNR1 (0.56) | CNR1CNR2KCNH2 | |
| SCHEMBL38658599 | 0.87 | CNR1 (0.69) | CNR1CNR2KCNH2 | |
| SCHEMBL5238025 | 0.87 | CNR1 (0.69) | CNR1CNR2KCNH2 | |
| SCHEMBL5239405 | 0.84 | CNR1 (0.78) | CNR1CNR2KCNH2 | |
| SCHEMBL5235129 | 0.84 | CNR1 (0.44) | CNR1CNR2KCNH2 | |
| SCHEMBL5236352 | 0.81 | CNR1 (0.81) | CNR1CNR2KCNH2 | |
| SCHEMBL5870669 | 0.80 | CNR1 (0.59) | CNR1CNR2KCNH2 | |
| SCHEMBL5237151 | 0.80 | CNR1 (0.71) | CNR1CNR2KCNH2 | |
| SCHEMBL5240453 | 0.76 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL16418419 | 0.76 | CNR1 (0.69) | CNR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100478343-C | Purine compound and use as cannabinoid receptor ligands | PFIZER (US) | 2009-04-15 | — | — | CN | disclosed |
| CN-100439369-C | Purine compounds and their use as cannabinoid receptor ligands | PFIZER (US) | 2008-12-03 | — | — | CN | disclosed |
| EP-1558615-B8 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1558615-B1 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2007-08-29 | — | — | EP | disclosed |
| CN-1955182-A | Purine compound and use as cannabinoid receptor ligands | PFIZER (US) | 2007-05-02 | — | — | CN | disclosed |
| CN-1955181-A | Purine compound and use as cannabinoid receptor ligands | PFIZER (US) | 2007-05-02 | — | — | CN | disclosed |
| US-7129239-B2 | Purine compounds and uses thereof | PFIZER INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060241120-A1 | Cannabinoid Receptor Ligands and Uses Thereof | PFIZER INC | 2006-10-26 | — | — | US | disclosed |
| CN-1708499-A | Purine compounds and their use as cannabinoid receptor ligands | PFIZER (US) | 2005-12-14 | — | — | CN | disclosed |
| EP-1558615-A1 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040092520-A1 | Purine compounds and uses thereof | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| WO-2004037823-A1 | PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241120-A1 | Cannabinoid Receptor Ligands and Uses Thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885KCNH2 2953/4885 |
| US-20040092520-A1 | Purine compounds and uses thereof | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885KCNH2 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.